NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 30 ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Harrow and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 8, 2025, Harrow issued ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy on its platform [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers and its executives made false or misleading statements and failed to disclose the risks associated with their practices, which jeopardized patient safety [2]. - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing deceptive promotion and selling of illegitimate versions of Wegovy [3]. Stock Impact - Following the announcement of the termination of the partnership, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [4].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for alleged misrepresentations regarding its ability to achieve sustainable and profitable growth [3]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of California on behalf of investors who purchased Petco securities between January 14, 2021, and June 5, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 29, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its inception in 1993 and has represented both individual investors and large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, is investigating whether BellRing Brands, Inc. (NYSE: BRBR), or any of its executive officers, violated securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased BRBR securities? If you purchased securities and suffered losses on your investment, join our investigation now: [Click Here to Join the Investigation] Or for more information, contact Jim Bake ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation is effective July 10, 2025, and he is leaving to pursue other endeavors [1][2] - Bellemin's departure aligns with the terms of his executive employment agreement, and a successor has not yet been named [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has faced significant commercial setbacks, with first-quarter sales underperforming Wall Street expectations [3] - The company has revised its full-year revenue projections downward, leading to a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is defending against a class-action securities fraud lawsuit related to its portrayal of authorized treatment centers (ATCs) crucial for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 per share to $1.75 per share within a day [6][7] - The market's swift reaction reflects investor concerns regarding the company's commercial execution and the accuracy of its operational updates [7]

Core Viewpoint - The Compass Diversified class action lawsuit alleges violations of the Securities Exchange Act of 1934 by the company and its executives, primarily related to misleading financial statements and irregularities in its subsidiary, Lugano Holdings [1][4][5]. Group 1: Lawsuit Details - The lawsuit is titled Augenbaum v. Compass Diversified Holdings, No. 25-cv-01003 (C.D. Cal.) and seeks to represent purchasers of Compass Diversified Holdings publicly traded securities [1]. - The class action lawsuit claims that Compass Diversified made false statements and failed to disclose significant financial irregularities related to Lugano Holdings, which affected the reported financial results for fiscal 2024 [4][5]. - The lawsuit was initiated after Compass Diversified announced the need to restate its 2024 financial statements due to identified irregularities in Lugano's accounting practices, leading to a stock price drop of over 62% [5]. Group 2: Financial Impact - The acquisition of Lugano Holdings was announced on September 7, 2021, with an enterprise value of $256 million [3]. - Following the announcement of the need for financial restatement, Compass Diversified's stock experienced a significant decline, indicating a loss of investor confidence [5]. Group 3: Legal Representation - The plaintiffs are represented by Robbins Geller Rudman & Dowd LLP, a law firm with extensive experience in prosecuting investor class actions, particularly those involving financial fraud [6][8]. - The firm has a strong track record, having recovered over $2.5 billion for investors in securities-related class action cases in 2024 alone [8].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Harrow reported first-quarter 2025 revenue of $47.8 million, which missed consensus estimates of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, falling short of the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on the same day [3]